Aaron Kantoff's Disposition of Tourmaline Bio, Inc. Shares and Stock Options

On October 28, 2025, Aaron Kantoff, a director of Tourmaline Bio, Inc., disposed of 88,281 shares of common stock and 26,800 stock options as part of a merger agreement with Novartis AG. The shares were tendered for $48.00 per share, and the stock options were canceled in exchange for cash payments based on the difference between the merger consideration and the exercise prices of the options. This transaction was executed pursuant to the Agreement and Plan of Merger dated September 8, 2025, which resulted in the acquisition of all outstanding shares of Tourmaline Bio, Inc. by Novartis AG through its subsidiary, Torino Merger Sub Inc.